AllSci News
FDA grants Fast Track Designation to Sobi's pacritinib for VEXAS syndrome
Swedish Orphan Biovitrum AB (Stockholm: SOBI), operating through its North American affiliate Sobi North America, announced that the US FDA has granted Fast...
Encoded Therapeutics raises USD 275m to push ETX101 toward pivotal Dravet syndrome trial
South San Francisco-based Encoded Therapeutics has closed a USD 275 million Series F financing round to advance its lead gene therapy candidate through...
CONNECTA raises EUR 3.1m to advance TrkB modulator into mid-stage Fragile X trial
Barcelona-based CONNECTA Therapeutics has closed a EUR 3.1 million (USD 3.4 million) financing round to support the clinical development of CTH120, its...
Ethris secures EUR 30m to advance broad-spectrum nasal antiviral into Phase IIb trials
Germany-based Ethris GmbH has secured EUR 30 million to support the advance of its mRNA-based respiratory treatments into later-stage trials. The financing...
Cerenome secures USD 20m royalty-based financing to scale CNSide diagnostics platform
Houston-based Cerenome, Inc. (Nasdaq: CNSY) has secured a senior secured financing facility of up to USD 20 million from 3i, LP, structured with...
Third Arc Bio advances first masked CD3 TCE under expanded Adagene collaboration
Third Arc Bio has selected its first lead candidate under an amended strategic collaboration with Adagene Inc. (Nasdaq: ADAG), triggering an expansion of...
FDA pauses enrollment in Biohaven’s opakalim trials; pivotal readout remains on track
A partial clinical hold on opakalim (BHV-7000), Biohaven Ltd.'s (NYSE: BHVN) selective Kv7.2/7.3 potassium channel activator in pivotal development for...
NeOnc raises USD 15m to advance Phase II CNS cancer programs after NEO100 efficacy readout
California-based NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) announced a USD 15 million registered direct offering on September 9, 2026, with proceeds...
AbbVie's atogepant meets primary endpoint in Phase III menstrual migraine trial
Atogepant (Qulipta/Aquipta) met the primary endpoint and all eight ranked secondary endpoints in the Phase III LUNA trial evaluating preventive treatment of...
ViaNautis expands into spinal cord injury with SCI Ventures backing for polyNaut platform
Cambridge, UK-based ViaNautis Bio has secured investment from SCI Ventures to expand its non-viral genetic medicine delivery platform into chronic spinal...
NodThera rebrands as Rezera as ruvonoflast meets Phase II endpoint, eyes Phase III in PAD
Ruvonoflast (NT-0796), an oral NLRP3 inflammasome inhibitor developed by Boston-based Rezera Inc. (formerly NodThera), met its primary endpoint in the...
Mindera Health partners with UPenn to investigate quinacrine mechanism in lupus
Mindera Health is collaborating with University of Pennsylvania researchers to investigate why quinacrine helps some patients with cutaneous lupus—and...
Seismic launches global Phase III trial of istaroxime in cardiogenic shock
Durham, North Carolina-based Seismic Pharmaceuticals has launched a global Phase III trial of istaroxime in cardiogenic shock, a life-threatening condition...
UpDoc receives up to USD 9.2m from ARPA-H for autonomous heart failure AI system
Palo Alto-based UpDoc has been selected as a lead performer in the Advanced Research Projects Agency for Health (ARPA-H) ADVOCATE program, receiving an...
Cytonics crowdfunds USD 4.8m to advance A2M biologic into Phase Ib/IIa osteoarthritis study
Jupiter, Florida-based Cytonics Corporation has completed a USD 4.8 million gross-proceeds financing campaign, bringing total capital raised to USD 47...
The AllSci Brief
Free, systematic R&D and deal news. Daily.